quarters if the u.k. is the 1st country to start rolling out this vaccine well that means few of are seen those as for other countries welcome production keep. well be out by on take try so make sure that everyone all of the customers do not get concerned about this $800000.00 those isto says it will now be delivered 1st to the u.k. but many more doses are expected to be delivered as soon as you know the vaccination is being confirmed also in europe biotech says it plans to deliver 1300000000 doses of the vaccine next year alone and let's not forget it's not going to be an easy task you have to store the vaccine at temperatures down to say minus 70 degrees celsius in order to make sure that this works there's a lot of technology involved. because of the vaccine is about to go into the market

how much of these companies charging and who's making the lion's share of the money they're fine. well the price is not something that the companies are really like to talk about. they have different prices for different countries and they also depending on when they develop for it to negotiate renegotiate the prices but the buy on tech vaccine is expected to cost $40.00 per shot. vaccine developed in the united states as well the astra zeneca vaccine developed in the u.k. is considered to be much much cheaper it's likely that later after the pandemic. the immediate risk of the pandemic is in check it's likely that those vaccines will cost more before that at the very beginning of the fight against the pandemic it's likely that the prices will be relit

a bit lower because of course the companies don't want to appear to be the big money makers only in this game. as you just mentioned it this this vaccine one of the disadvantages it has is that it has to be stored and transported at minus 70 degrees celsius but how will authorities and of the health systems deal with that well pfizer says that they spent a lot of manpower and money putting together these ship shipment units which can store this vaccine for up to $30.00 days at $9070.00 degrees using a very serious can of dry ice and replenish the dry ice every few days it's not it's not straightforward but they say they've got a system in place that can get it to the far end of the world and then a low local authorities local pet public health authorities to then distribute it to pharmacies or hospitals where they are it can be stored in normal

refrigerators between $2.00 and $8.00 degree celsius for up to 5 days and slot with a critical period where so that doesn't have to be kept at minus 70 all the time so there's a bit of a window that basically that's right it's there's a window there which which i think is a we'll we'll we'll figure out how to get it to you. to the area to the country and then it will be a case of movie really quickly to get fridges which is more like kind of commercial fridges can can handle 2 to a degree celsius and then from there it's about just does it get out quickly enough and when does it begin to spoil pfizer says 5 days may vary depending on the boche . what is in your opinion going to be the biggest challenge producing enough doses or distributing to the far corners of the world i suspect there

is a mix of the 2 i mean i think it's worth once there will be snags along the way in the try figure out ok how can we can we fix this because it's not just pfizer by own tech it's also all the big cargo companies. d.h. you know all these all these organizations that are are set to make money as well let's not forget as there's a benefit for their so they try to figure out ok where where are we able to to move things quicker and i think other things to remember this is a huge breakthrough it's just part of the portfolio vaccinations on offer as conrad was saying you got one down seneca sanofi a bunch of others so it's just going to be that the 1st one obviously so highly anticipated and people desperate to get $100.00 up there would be the only. the the next big must of course being the 1st little of your patients of course hopefully very soon so let's talk a bit about the timeline of the vaccine how was it so fast wow i think it was a combination of things so m.r.

any technology allows you although it's complicated and you know we have these problems with the with storing extremely cold temperatures allows you to genetically design a lot scene much quicker than traditional vaccination. than traditional vaccinations which which require multiple testing going back and forth finding a kind of. a longer kind of free time frame but basically what they said was it was quicker and then authorities like regulators said we will give you we will start to look at the data as you are. getting it so that it was happening a jew speed it wasn't like we do it at a phase they get it over to the regulators it was happening at the same time it's called a ruling. authorization they were going to talk about this a bit more after the press conference which i think is about to start right now not

yet oh ok let's go to conrad. i don't know whether he's still with us in front of the biotech headquarters in my eyes yes there is still the the what will this this breakthrough the with this vaccine do for the value of the company that you're standing in front of. well let me tell you what it how it really has done the expectation of this vaccine has pushed the share price of buy on tech ok. here's a robin yeah because the press conferences are biotech has just started their work has been granted for face free clinic or data backed covert 916 by the m h r aver a u.k. regulatory agency we have started immediately the process of delivering our vaccine. i started with this one with delivering our vaccine

and we expect that the role of a vaccine in the u.k. will happen within the next couple of days secondly what we would like to report that on monday. bidding on rolling revenue which was initiated in october of this year we have family fired an epic asian for conditional market marketing offer rise ation with a european medicines agency with e m a. buy on tech would be even a marketing offer arise ation holder fava e.u. u.k. and the us and various other countries a lot esteemed part not 5 with do of the marketing of a marketing and of a distribution in these and various other countries. let me briefly show you

a high level overview about johnny and the last couple of months we called our development program for a covert 19 vaccine project light speech because you can't go faster than light and this was what we aimed for the steer any started in january vess year and was devoted to vote development of in very top rated and effective covert 1000 vaccine following the highest scientific and ethical standards this was a journey of 111211 months which started with engineering my to peer potential candidates fixing candidates of which several entered clinical testing phase one in a previous year in july we selected to cover with our partner fires are

one of those candidates the most promising one for phase 3 trial and in november of this year we quite report fet in this trial a lot of x. in hazmat odd primary efficacy and points. on the next slide you can see that project lightspeed as in fact global concerted largest scale effort of history try it has been conducted in my to pair countries in the u. s. and t. nya brazil germany south africa and in turkey. have a face reach trial has reached a final and points in mich november in addition to that we have regular regulatory submissions on a rolling basis ongoing not only in the e.u.

but also additional countries such as canada and australia we have in addition an epi cation at the u s f t a for emergency use off arise ation of our vaccine in in the us and we are awaiting decisions 5 or f.d.a. mitch of december and this is also of a time arise and in which we expect decisions off e m a on our conditional marketing fries ation application we have ongoing tryouts in japan and together with our partner for so on we have an ongoing face to try out with b. and he won $62.00 b. to our vaccine in china and on top of these of this program there are rolling submissions to a 2 fer of our country's plant. in control of her

randomized blinded face retrial. the 162 b. 2. $62.00 b. 2 was tested at 2 injections off of x. in $21.00 days apart at relatively low dose of fruity mic s. compared to 2 placebo heavy participants were eligible for office clinical trial in total more than 40 free 1000 subjects were immunize mostly 18 to 85 years of age an independent data monitoring committee assessed if it can see off of ecstasy in a ficus e was assessed based on the number of confirmed covert 19 cases starting 7 days after the 2nd injection in the press evil 162 cases of covert were reported wired in.

a way fx in a to sub subjects we counted 8 cases this is a vaccine if we can see off 95 percent you can see on the slide that. this high vix seen efficacy was observed across separations including you know all age groups also including older diet's off 65 years and age across ethnicities and also across gender us. independent daytime monitoring committee did not know what any serious safety concerns in fact all vaccine was whether tolerate church we are served a common reactions you would have with vaccination ink. pain

adventure injection side fatigue headache must so pain most and generally these reactions were a mild to moderate and short lift a tourist events of great free or very rare we observed only a fatigue in 4 percent of participants and a headache in 2 percent of a vet of participants and about not 98 percent of participants who've received the 1st dose came back for a 2nd shot we will continue to follow up of a participants in our clinic or try outs for a ficus and also for safety for 2 years and would report on a lot of savation as they come come up with this i watch then hand over to to. yeah thank thank thank you asked them.

co-founder and c.e.o. of bio tech and i would like to give you give you a back around about the science behind messenger on a vaccines and would also like to introduce you. use for background information about messenger r.n.a. as a molecule so the message on a is a. is a new track entity so it is not yet approved and if this vaccine is going to be approved it will be the 1st messenger on a plaque which which would be available as a pharmaceutical poor that. however messenger on a value known molecule it's actually the 1st molecule off life it emerged many 1000000000 years ago and we have a human being. every animal has messenger r.n.a.

in the cells so messenger on a is an intermediate molecules or so many many people know the aid which has the stable genetic information and messenger r.n.a. is produced in south and after being put to use it serves as a template to make proteins but what is important is not a stable molecule it's active only for a few days and is degraded by the cellular machinery within a few days and our messenger r.n.a. which we use which we use for making the b n t $162.00 b. 2 vaccine this is mimics the national natural m. on a moloch molecule and it has no no no that components and then the naturally value known molecules it is constantly active like any other natural.